What this trial means for you
This study is opening soon at 1 US site. It's studying GLP1 receptor agonist for lower urinary tract symptoms, stress urinary incontinence, urge urinary incontinence.
What participants typically get: study medication (or placebo, if the trial uses one) and study-related medical care at no cost, plus close monitoring. Compensation for time and travel varies by study — ask the site. Note that in many trials you can't choose your treatment group, and some participants receive a placebo.
The study, in the sponsor's words
The purpose of this study is to compare change in pelvic floor symptoms between patients receiving medical therapy for weight loss and surgical treatment for weight loss. Examples of pelvic floor symptoms include urinary incontinence, urinary urgency, urinary frequency, fecal incontinence, and vaginal prolapse. Participants in this study do not need to have any pelvic floor symptoms to enroll in the study. Understanding how different types of weight loss treatment impact pelvic floor symptoms will help clinicians guide which weight loss treatments are recommended for patients with pelvic floor symptoms in the future.
Can you join? The exact criteria
Below is the verbatim eligibility text from the registry — bring it to your doctor; it's written for clinicians, and your own clinician is the right person to interpret it with you.
Full eligibility criteria (for you and your doctor)
Inclusion Criteria: * female * 18-89 years old * any race/ethnicity * BMI ≥30 kg/m2 * current medical weight loss or surgical weight loss patient of Obesity Medicine and Metabolic \& Bariatric Surgery * able/willing to give informed consent * have a home scale to measure weight Patients meeting all the following criteria will be eligible to participate in the medical weight loss therapy arm: * prescribed and start a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or a GLP-1/gastric inhibitory peptide (GIP1) * taking other weight loss agents (such as metformin) Patients meeting all the following criteria will be eligible to participate in the bariatric surgery arm: * plan to undergo gastric sleeve or gastric bypass surgery * taking weight loss agents which are not GLP-1 RA or GLP-1/GIP1 medications at the start of the study. Patients will not be excluded if they are started on GLP-1 RA or GLP-1/GIP1 medications after surgery. Exclusion Criteria: * Pregnant * ≥90 years old * \<18 years old * BMI \<30 kg/m2 * A history of bariatric surgery prior to enrollment * No home scale to measure weight * Active cancer
Study sites by state
Connecticut
- Hartford Hospital — Hartford
View the official record on ClinicalTrials.gov →
Follow this trial
Get an email when our monthly digest covers enrollment changes and results for trials like this one.
Newsletter signup launches soon. (Site owner: set PUBLIC_BUTTONDOWN_USERNAME in
.env to activate this form.)